The effects of radiation on antitumor efficacy of an oncolytic adenovirus vector in the Syrian hamster model

Cancer Gene Therapy

Volumn 20, Issue 9, 2013, Pages 531-537

  Young, B A ^a   Spencer, J F ^a   Ying, B ^a   Toth, K ^a   Wold, W S M ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

adenovirus; hamster; radiation; replicating; tumor; virotherapy

Indexed keywords

ADENOVIRUS VECTOR; CYCLOPHOSPHAMIDE; ONCOLYTIC ADENOVIRUS; UNCLASSIFIED DRUG; VRX 007;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; FEMALE; GROWTH INHIBITION; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; RADIATION; RADIOTHERAPY; SYRIAN HAMSTER; TUMOR GROWTH; TUMOR VOLUME; VIRUS REPLICATION;

ADENOVIRIDAE; CRICETINAE; MESOCRICETUS AURATUS;

ADENOVIRIDAE; ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; CELL LINE, TUMOR; CRICETINAE; CYCLOPHOSPHAMIDE; FEMALE; GENETIC VECTORS; HUMANS; NEOPLASMS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; RADIATION; TUMOR BURDEN; VIRUS REPLICATION;

EID: 84884592718     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2013.50     Document Type: Article

References (44)

1. Toth K, Wold WS. Increasing the efficacy of oncolytic adenovirus vectors. Viruses 2010; 2: 1844-1866.
2. Yamamoto M, Curiel DT. Current issues and future directions of oncolytic adenoviruses. Mol Ther 2010; 18: 243-250.
3. Pesonen S, Kangasniemi L, Hemminki A. Oncolytic adenoviruses for the treatment of human cancer: focus on translational and clinical data. Mol Pharm 2011; 8: 12-28.
4. Liu TC, Galanis E, Kirn D. Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress. Nat Clin Pract Oncol 2007; 4: 101-117. (Pubitemid 46189539)
5. Yu W, Fang H. Clinical trials with oncolytic adenovirus in China. Current Cancer Drug Targets 2007; 7: 141-148. (Pubitemid 46348628)
6. Ottolino-Perry K, Diallo JS, Lichty BD, Bell JC, McCart JA. Intelligent design: combination therapy with oncolytic viruses. Mol Ther 2010; 18: 251-263.
7. Doronin K, Toth K, Kuppuswamy M, Ward P, Tollefson AE, Wold WSM. Tumorspecific, replication-competent adenovirus vectors overexpressing the Adenovirus Death Protein. J Virol 2000; 74: 6147-6155. (Pubitemid 30412986)
8. Doronin K, Toth K, Kuppuswamy M, Krajcsi P, Tollefson AE, Wold WSM. Overexpression of the ADP (E3-11.6K) protein increases cell lysis and spread of adenovirus. Virology 2003; 305: 378-387. (Pubitemid 36259672)
9. Tollefson AE, Scaria A, Hermiston TW, Ryerse JS, Wold LJ, Wold WSM. The adenovirus death protein (E3-11.6K) is required at very late stages of infection for efficient cell lysis and release of adenovirus from infected cells. J Virol 1996; 70: 2296-2306. (Pubitemid 26087592)
10. Doronin K, Kuppuswamy M, Toth K, Tollefson AE, Krajcsi P, Krougliak V et al. Tissue-specific, tumor-selective, replication-competent adenovirus vector for cancer gene therapy. J Virol 2001; 75: 3314-3324. (Pubitemid 32225894)
11. Toth K, Kuppuswamy M, Shashkova EV, Spencer JF, Wold WSM. A fully replicationcompetent adenovirus vector with enhanced oncolytic properties. Cancer Gene Ther 2010; 17: 761-770.
12. Toth K, Spencer JF, Tollefson AE, Kuppuswamy M, Doronin K, Lichtenstein DL et al. Cotton rat tumor model for the evaluation of oncolytic adenoviruses. Hum Gene Ther 2005; 16: 139-146. (Pubitemid 40250340)
13. Thomas MA, Spencer JF, Toth K, Sagartz JE, Phillips N, Wold WSM. Immunosuppression enhances oncolytic adenovirus replication and anti tumor efficacy in the Syrian hamster model. Mol Ther 2008; 16: 1665-1673.
14. Dhar D, Spencer JF, Toth K, Wold WSM. Effect of preexisting immunity on oncolytic adenovirus vector INGN 007 antitumor efficacy in immunocompetent and immunosuppressed Syrian hamsters. J Virol 2009; 83: 2130-2139.
15. Spencer JF, Sagartz JE, Wold WSM, Toth K. New pancreatic carcinoma model for studying oncolytic adenoviruses in the permissive Syrian hamster. Cancer Gene Ther 2009; 16: 912-922.
16. Sonabend AM, Ulasov IV, Han Y, Rolle CE, Nandi S, Cao D et al. Biodistribution of an oncolytic adenovirus after intracranial injection in permissive animals: a comparative study of Syrian hamsters and cotton rats. Cancer Gene Ther 2009; 16: 362-372.
17. Thomas MA, Spencer JF, La Regina MC, Dhar D, Tollefson AE, Toth K et al. Syrian hamster as a permissive immunocompetent animal model for the study of oncolytic adenovirus vectors. Cancer Res 2006; 66: 1270-1276. (Pubitemid 43259903)
18. Bortolanza S, Bunuales M, Otano I, Gonzalez-Aseguinolaza G, Ortiz-de-Solorzano C, Perez D et al. Treatment of pancreatic cancer with an oncolytic adenovirus expressing interleukin-12 in Syrian hamsters. Mol Ther 2009; 17: 614-622.
19. Rogulski KR, Freytag SO, Zhang K, Gilbert JD, Paielli DL, Kim JH et al. In vivo antitumor activity of ONYX-015 is influenced by p53 status and is augmented by radiotherapy. Cancer Res 2000; 60: 1193-1196. (Pubitemid 30151981)
20. Wold WSM, Ison MG. Adenoviruses. In: Knipe DM, Howley PM (eds) Fields Virology. 6 edn, vol. 1. Lippincott Williams & Wilkins: Philadelphia, pp 1732-1767, 2013.
21. Thomas O, Mahe MA, Campion L, Bourdin S, Milpied N, Brunet G et al. Long-term complications of total body irradiation in adults. Int J Radiat Oncol Biol Phys 2001; 49: 152-131.
22. Toth K, Tarakanova V, Doronin K, Ward P, Kuppuswamy M, Locke JL et al. Radiation increases the activity of oncolytic adenovirus cancer gene therapy vectors that overexpress the ADP (E3-11.6K) protein. Cancer Gene Ther 2003; 10: 193-200. (Pubitemid 36348680)
23. Thomas MA, Spencer JF, Wold WSM. Use of the Syrian hamster as an animal model for oncolytic adenovirus vectors. In: Tollefson AE, Wold WSM (eds). Methods in Molecular Medicine, vol 1. 2nd edn. Humana Press: Totowa, pp 169-183, 2007.
24. Lichtenstein DL, Toth K, Doronin K, Tollefson AE, Wold WSM. Functions and mechanisms of action of the adenovirus E3 proteins. Int Rev Immunol 2004; 23: 75-111. (Pubitemid 38121748)
25. Aste-Amezaga M, Bett AJ, Wang F, Casimiro DR, Antonello JM, Patel DK et al. Quantitative adenovirus neutralization assays based on the secreted alkaline phosphatase reporter gene: application in epidemiologic studies and in the design of adenovector vaccines. HumGene Ther 2004; 15: 293-304. (Pubitemid 38365918)
26. Jemal A, Siegel R, Ward E, Murray T, Xu JQ, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007; 57: 43-66.
27. Tysome J, Li X, Wang S, Wang P, Gao D, Du P et al. A novel therapeutic regimen to eradicate established solid tumors with an effective induction of tumor-specific immunity. Clin Cancer Res 2012; 18: 6679-6689.
28. Hu W, Davis JJ, Zhu H, Dong F, Guo W, Ang J et al. Redirecting adaptive immunity against foreign antigens to tumors for cancer therapy. Cancer Biol Ther 2007; 6: 1773-1779. (Pubitemid 351590312)
29. Dhar D, Spencer JF, Toth K, Wold WSM. Pre-existing immunity and passive immunity to adenovirus 5 prevents toxicity caused by an oncolytic adenovirus vector in the Syrian hamster model. Mol Ther 2009; 17: 1724-1732.
30. Begg AC, Stewart FA, Vens C. Strategies to improve radiotherapy with targeted drugs. Nat Rev Cancer 2011; 11: 239-253.
31. Chu RL, Post DE, Khuri FR, Van Meir EG. Use of replicating oncolytic adenoviruses in combination therapy for cancer. Clin Cancer Res 2004; 10: 5299-5312. (Pubitemid 39100464)
32. Rajecki M, Hallstrom T, Hakkarainen T, Nokisalmi P, Hautaniemi S, Nieminen AI et al. Mre11 inhibition by oncolytic adenovirus associates with autophagy and underlies synergy with ionizing radiation. Int J Cancer 2009; 125: 2441-2449.
33. Huh JJ, Wolf JK, Fightmaster DL, Lotan R, Follen M. Transduction of adenovirusmediated wild-type p53 after radiotherapy in human cervical cancer cells. Gynecol Oncol 2003; 89: 243-250. (Pubitemid 36457872)
34. Kuroda S, Fujiwara T, Shirakawa Y, Yamasaki Y, Yano S, Uno F et al. Telomerasedependent oncolytic adenovirus sensitizes human cancer cells to ionizing radiation via inhibition of DNA repair machinery. Cancer Res 2010; 70: 9339-9348.
35. Dai MH, Zamarin D, Gao SP, Chou TC, Gonzalez L, Lin SF et al. Synergistic action of oncolytic herpes simplex virus and radiotherapy in pancreatic cancer cell lines. Br J Surg 2010; 97: 1385-1394.
36. Gallardo D, Drazan KE, McBride WH. Adenovirus-based transfer of wild-type p53 gene increases ovarian tumor radiosensitivity. Cancer Res 1996; 56: 4891-4893. (Pubitemid 26374425)
37. Spitz FR, Nguyen D, Skibber JM, Meyn RE, Cristiano RJ, Roth JA. Adenoviralmediated wild-type p53 gene expression sensitizes colorectal cancer cells to ionizing radiation. Clin Cancer Res 1996; 2: 1665-1671. (Pubitemid 26356349)
38. Liu C, Zhang Y, Liu MM, Zhou H, Chowdhury WH, Lupold SE et al. Evaluation of continuous low dose rate versus acute single high dose rate radiation combined with oncolytic viral therapy for prostate cancer. Int J Radiat Biol Relat Stud Phys Chem Med 2010; 86: 220-229.
39. Nandi S, Ulasov IV, Tyler MA, Sugihara AQ, Molinero L, Han Y et al. Low-dose radiation enhances survivin-mediated virotherapy against malignant glioma stem cells. Cancer Res 2008; 68: 5778-5784.
40. Advani SJ, Sibley GS, Song PY, Hallahan DE, Kataoka Y, Roizman B et al. Enhancement of replication of genetically engineered herpes simplex viruses by ionizing radiation: a new paradigm for destruction of therapeutically intractable tumors. Gene Ther 1998; 5: 160-165. (Pubitemid 28077742)
41. Lamfers ML, Grill J, Dirven CM, Van Beusechem VW, Geoerger B, Van Den BJ et al. Potential of the conditionally replicative adenovirus Ad5-Delta24RGD in the treatment of malignant gliomas and its enhanced effect with radiotherapy. Cancer Res 2002; 62: 5736-5742. (Pubitemid 35204729)
42. Wein LM, Wu JT, Kirn DH. Validation and analysis of a mathematical model of a replication-competent oncolytic virus for cancer treatment: implications for virus design and delivery. Cancer Res 2003; 63: 1317-1324. (Pubitemid 36348711)
43. Kim J, Kim PH, Yoo JY, Yoon AR, Choi HJ, Seong J et al. Double E1B 19kDa-and E1B 55kDa-deleted oncolytic adenovirus in combination with radiotherapy elicits an enhanced anti-tumor effect. Gene Ther 2009; 16: 1111-1121.
44. Kurozumi K, Hardcastle J, Thakur R, Yang M, Christoforidis G, Fulci G et al. Effect of tumor microenvironment modulation on the efficacy of oncolytic virus therapy. J Natl Cancer Inst 2007; 99: 1768-1781. (Pubitemid 351767207)